Contenido en inglés
An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’
En resumen
AstraZeneca shares were slumping while Bristol-Myers Squibb’s stock was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.
- Fuente primaria
- MarketWatch.com - Top Stories — Leer artículo original
- Publicado
- Tema
- Finanzas
AstraZeneca shares were slumping while Bristol-Myers Squibb’s stock was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.
Este resumen proviene de MarketWatch.com - Top Stories. Lee el artículo completo en la fuente original.
Referencias
Más en Finanzas
As ‘Spider-Man’ joins ‘The Odyssey’ in Imax, are premium movie screens worth the extra price?
Some movie fans call premium screenings a “gimmick.” Others are driving six hours to see “The Odyssey” in Imax 70mm.
These are the stocks posting the largest moves after the bell.
This indicator is giving the bull market another lease on life
Stock-market timers recently rushed to the exits, which is bullish from a contrarian perspective.
¿Habrá secuela de ‘Barbie’? Los millonarios sueldos de Margot Robbie y Ryan Gosling complican una nueva película
Parece que, al final, Barbie no lo puede todo. La secuela de la exitosa película inspirada en la muñeca está en el limbo, pues Warner Bros. ( WBD ) aún no logra un acuerdo para el…